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Inhibition of Melanogenesis by the Antidiabetic
Metformin
Abdelali Lehraiki1,2, Patricia Abbe1,2, Michael Cerezo1,2, Florian Rouaud1,2, Claire Regazzetti2,3,
Be´renge`re Chignon-Sicard4, Thierry Passeron2,3,5, Corine Bertolotto1,2,5, Robert Ballotti1,2,5
and Ste´phane Rocchi1,2,5
Several reports have demonstrated the inhibitory effect of metformin, a widely used drug in the treatment of
type 2 diabetes, on the proliferation of many cancers including melanoma. Recently, it has been shown that
metformin is able to modulate the cAMP level in the liver. As cAMP has a crucial role in melanin synthesis and
skin pigmentation, we investigated the effect of metformin on melanogenesis both in vitro and in vivo. We
showed that metformin led to reduced melanin content in melanoma cells and in normal human melanocytes by
decreasing cAMP accumulation and cAMP-responsive element–binding protein phosphorylation. This inhibitory
effect is correlated with decreased expression of master genes of melanogenesis, microphthalmia-associated
transcription factor, tyrosinase, dopachrome tautomerase, and tyrosinase-related protein 1. Furthermore, we
demonstrated that the antimelanogenic effect of metformin is independent of the AMPK pathway. Interestingly,
topical application of metformin induced tail whitening in mice. Finally, we confirmed the antimelanogenic effect
of metformin on reconstituted human epidermis and on human skin biopsies. These data emphasize the
depigmenting effect of metformin and suggest a clinical strategy for using metformin in the topical treatment of
hyperpigmentation disorders.
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INTRODUCTION
Melanocytes are specialized cells located at the basal layer
of the epidermis that produce and transfer melanin pigments
to the surrounding keratinocytes. Melanin is principally
responsible for skin color and has an important role in the
prevention of sun-induced skin injury. Three melanocyte-
specific enzymes, tyrosinase, tyrosinase-related protein 1
(TRP1), and dopachrome tautomerase (DCT), are involved
in this enzymatic process that converts tyrosine to melanin
pigments (Kobayashi et al., 1994; Passeron et al., 2005).
Melanin synthesis is stimulated by different factors inclu-
ding UV irradiation, alpha-melanocyte-stimulating hormone
(a-MSH), or cAMP-elevating agents such as forskolin
(Yamaguchi and Hearing, 2009). These stimuli activate the
cAMP pathway in which the microphthalmia-associated
transcription factor (MITF) is the most important target.
Indeed, binding of a-MSH to melanocortin-1 receptor leads
to adenylate cyclase increase, elevation of intracellular cAMP,
and activation of protein kinase A (PKA). cAMP-activated PKA
is then transferred to the nucleus and it phosphorylates its
principal substrate cAMP-responsive element–binding protein
(CREB). Phosphorylated CREB upregulates the transcription of
genes whose promoters have a cAMP-response element
sequence, and thus induces the expression of MITF, the master
regulator in the transcription of genes involved in melanin
synthesis such as tyrosinase, TRP1, and DCT (Bertolotto et al.,
1996; Busca and Ballotti, 2000). Deregulation of this signaling
pathway may cause pigmentation disorders.
There are numerous causes of hyperpigmentation, such as
postinflammatory etiologies, hormonally mediated factors,
cosmetics, drug-induced causes, and UV radiation in addition
to systemic conditions such as Addison’s disease and Wilson’s
disease. These pigmentation disorders have traditionally been
a relatively difficult condition to treat, and currently used
depigmentating agents have little effect with sometimes severe
side effects (Solano et al., 2006).
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The oral antidiabetic drug metformin belongs to the family
of biguanide drugs and is the most widely used antidiabetic
drug in the world. This drug has been shown to inhibit
the energy-sensitive AMP-activated protein kinase (AMPK)-
mammalian target of rapamycin signaling pathway that leads
to reduced protein synthesis and cell proliferation. Recent
studies indicate that metformin can potentially be used as an
efficient anticancer drug in various tumors (Ben Sahra et al.,
2010; Pollak, 2010). In addition, metformin was reported by
several groups, including ours, to inhibit the proliferation and
invasion of melanoma cells (Woodard and Platanias, 2010;
Janjetovic et al., 2011; Niehr et al., 2011; Tomic et al., 2011;
Cerezo et al., 2013). Interestingly, our previous work has
shown that metformin was nontoxic on normal cells such as
melanocytes, keratinocytes, or fibroblasts (Tomic et al., 2011
and unpublished results).
As it was recently shown that metformin decreases the
cAMP level (Miller et al., 2013) and that cAMP has a
crucial role in melanin synthesis and skin pigmentation,
we investigated the effect of metformin on pigmentation
in vitro and in vivo.
RESULTS
Metformin inhibits the synthesis and secretion of melanin by
melanoma cells in a time- and a dose-dependent manner
To assess the effect of metformin on melanogenesis, B16 cells
were stimulated by propigmenting agents a-MSH and forskolin
in the presence or absence of metformin. Visual evaluation
revealed a remarkable reduction in the melanin content
noticeable from 48 hours of treatment in cells stimulated with
forskolin but not in basal conditions (Figure 1a). Forskolin and
a-MSH induced a high increase in melanin content in
melanoma cells after 72 hours of treatment (Figure 1b). How-
ever, metformin significantly decreased the melanin synthesis
in basal, forskolin, and a-MSH conditions (Figure 1b). As
expected, melanin dosage indicated that both forskolin and
a-MSH stimulated melanin secretion in culture medium after
72 hours of treatment (Figure 1c). This increase was abolished
by metformin treatment.
Metformin inhibits melanogenesis gene expression in melanoma
cells and in normal human melanocyte (NHM) cells
To determine the mechanism of action of metformin on
melanin synthesis, we examined its effect on key proteins
involved in melanogenesis, such as MITF, tyrosinase, TRP1,
and DCT.
In B16 cells, treatment with forskolin or a-MSH significantly
increased protein levels of MITF, tyrosinase, and TRP1
(Figure 2a). However, we did not observe a significant change
in DCT protein expression. Treatment of cells with metformin
significantly reduced the levels of MITF, tyrosinase, TRP1, and
DCT. The effect is more pronounced when we cotreated
melanoma cells either with forskolin or a-MSH and metformin
(Figure 2a). In NHM cells, forskolin induced a slight increase
in MITF level compared with control (Figure 2b). NHM cells
contain high level of MITF, which can explain the absence of
stimulation on MITF level when we treated with forskolin.
Forskolin induced a significant increase of TRP1 and DCT
(Figure 2b). Treatment of NHM cells with metformin decreased
MITF, tyrosinase, and DCT levels in a dose-dependent manner
(Figure 2b). Interestingly, cotreatment of NHM cells with both
metformin and forskolin induced the extinction of MITF,
tyrosinase, and DCT. A decrease in MITF and genes of
melanogenesis was observed after 12 hours of metformin
treatment both in B16 cells and in NHM cells (Supple-
mentary Figure 3 online).
Metformin inhibits MITF promoter activity
As MITF, through the regulation of tyrosinase expression, is a
key factor in melanogenesis, we explored the possibility that
metformin regulates MITF expression through a transcriptional
regulation. To verify this, a luciferase-based promoter assay
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Figure 1. Antimelanogenic effect of metformin. B16-F10 cells at a density of 2.105 cells per well (six-well plate) were incubated overnight and were then
treated with metformin 5 10 mM (Met), forskolin 20mM (Fsk), alpha-melanocyte stimulating hormone (a-MSH) (10mM), or a combination of these drugs, as
indicated, for 12, 24, 48, or 72 hours. (a) Cell pellet images with or without the indicated treatment were taken using a digital camera. Melanin content
(72 hours treatment) (b) and melanin secretion in culture medium (72 hours treatment) (c) were measured with synthetic melanin as a standard and then
normalized to the protein fraction. The data show the mean±SD of five separate experiments (*Pp0.05; **Pp0.01; ***Pp0.001) versus control.
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was used in B16 cells by using vector encoding wild-type
MITF promoter (p-MITF), as described previously (Bertoloto
et al., 1996). As shown in Figure 2c, forskolin led to an
approximately fivefold increase of MITF promoter activity.
However, metformin significantly inhibited MITF promoter
activity both in basal and in forskolin-stimulated conditions,
demonstrating that metformin affects MITF transcription.
By using an MITF promoter containing a mutation in the
CREB-binding site, we showed that neither forskolin nor
metformin is able to modify CREB-mutated promoter activity
(Figure 2c). All together, these results demonstrate that
metformin is a specific inhibitor of MITF at the messenger
RNA expression level.
Metformin inhibits melanogenesis by decreasing the production
of cyclic AMP
cAMP-induced melanogenesis has been reported to be
mediated by the activation of PKA and CREB phosphorylation.
Treatment of B16 cells with forskolin or alpha-MSH
during 24 hours increased PKA and CREB phosphorylation,
whereas metformin induced a significant inhibition of protein
phosphorylation in both basal and stimulated conditions
(Figure 3a). No effect of metformin on PKA and CREB
expressions has been observed.
The same effect of metformin on CREB phosphorylation was
observed in NHM cells (Figure 3b). These results suggest that
metformin exerts its depigmenting effects on melanoma cells
and in melanocytes through the inhibition of CREB activation.
This effect might be due to an increase in cAMP level.
To verify this hypothesis, we measured the level of cAMP in
response to metformin. Both forskolin and a-MSH increased
cAMP in melanoma cells, with the maximum effect observed
after 6 hours of treatment (Figure 3c). Metformin decreased
cAMP accumulation in either forskolin- or a-MSH-stimulated
conditions in a time-dependent manner, with the maximum
effect observed after 48 hours of metformin treatment.
We next evaluated whether the diminution of the cAMP
level in response to metformin is involved in MITF down-
regulation. We used a membrane-permeable analog of cAMP:
dibutyryl cAMP. Treatment of B16 cells with dibutyryl cAMP
increases the levels of MITF protein and master genes of
melanogenesis. In the presence of dibutyryl cAMP, metformin
was unable to decrease MITF level as in control conditions
(Figure 3d).
Metformin reduced MITF by an AMPK-independent pathway
The anticancer effects of metformin have been essentially
attributed to its ability to activate the AMPK pathway.
To determine whether AMPK has a role in melanogenesis
inhibition by metformin, we abrogated AMPK activation
using a dominant negative form of AMPK both in NHM cells
(Figure 4a) and in Mel501 cells (Figure 4b). As expected,
infection of AMPK-DN increases the total level of AMPK and
inhibits partially (NHM) or totally (Mel501) the phosphory-
lation of AMPK and its downtream effector acetyl-CoA
carboxylase in basal and stimulated conditions, indicating
that the negative form of AMPK is expressed and is effective.
In Mel501 cells, we observed that AICAR, a specific activator
of AMPK, had no effect on MITF. Metformin decreased the
protein levels of MITF and of key proteins involved in
melanogenesis both in cells infected with control or AMPK-
DN adenovirus. These results suggest that the AMPK pathway
is not implicated in the antimelanogenic effect of metformin.
Similar results were obtained when AMPK was knocked down
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Figure 2. Metformin inhibits melanogenesis gene expression and microphthalmia-associated transcription factor (MITF) promoter activity. B16-F10 cells
(a) or normal human melanocytes (NHMs) (b) were treated with metformin 5 10 mM (Met), forskolin 20mM (Fsk), alpha-melanocyte stimulating hormone
(a-MSH) (10mM), or combinations of these drugs, as indicated, for 48 hours. Cell lysates were used for western blotting with indicated antibodies. (c) B16 cells
were transiently transfected either with 0.5mg of MITF promoter (p-MITF) (black bar) or pCMV–CREB133 (gray bar) (gift of Dr Mauviel Alain, Institut Curie,
Orsay, France) encoding the MITF promoter containing a mutation in the cAMP-responsive element–binding protein (CREB)-binding site and 0.05mg of pCMVbGal
to control the variability in transfection efficiency. Cells were treated for 48 hours with different drugs as indicated. Luciferase activity was normalized
to b-galactosidase activity and the results were expressed as fold stimulation of the basal luciferase activity from unstimulated cells. Data are means±SD
of five experiments performed in triplicate (**Pp0.01, ***Pp0.001, versus control 111Pp0.001 ). DCT, dopachrome tautomerase; TRP1, tyrosinase-related
protein 1.
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by using small interfering RNA (siRNA) in Mel501 cells
(Figure 4c).
Moreover, it has already been shown that LKB1 is the major
kinase phosphorylating the AMPK under conditions of energy
stress (Hardie et al., 2012). We thus evaluated the effect of
metformin on MITF protein level in G361 cells in which LKB1
is mutated. As shown in Figure 4d, metformin decreased
the levels of MITF and the master genes of melanogenesis in
G361 cells in basal and forskolin-stimulated conditions.
Metformin inhibits melanogenesis in vivo
To test whether the effects of metformin observed on mela-
nogenesis in vitro were representative of its action in vivo, we
examined the effect of metformin on tail pigmentation of
C57BL/6J mice. To this end, C57BL/6J mice were treated daily
by topical application of metformin (10 mM), forskolin (20mM),
or a combination during 8 weeks. As there is often a high
variability of pigmentation on the tip of mouse tails, we chose
them by taking into account the homogeneous pigmentation
in this area (Figure 5a). We showed that daily topical
application of forskolin had no effect on skin darkening
(Figure 5b); this observation was confirmed by the absence
of the effect of forskolin treatment on tail melanin content
(Figure 5c). Nonetheless, forskolin induced a significant
increase in DCT protein level and a slight increase in MITF
and tyrosinase protein level (Figure 5d). Contrary to forskolin,
daily topical application of metformin induced tail depigmen-
tation in mice (Figure 5b). This effect correlates with a
decrease in melanin content (Figure 5c) and with the level
of master melanogenic genes (Figure 5d). Interestingly, the
effect of metformin is more important when mice were
cotreated with forskolin.
Finally, we tested the effect of metformin on human
reconstituted epidermis. As presented in Figure 6a, direct
24 Hours
pPKA pCREB
12 H
ours
24 H
ours
48 H
ours
ERK2
pCREB
ERK2
ERK2
pCREB
PKA
pCREB
CREB
ERK2
25
Tyrosinase
DCT
24 Hours
TRP1
MITF
ERK2
Ctr
Me
t 1
0 m
M
db
cA
MP
 1 
mM
db
cA
MP
 +
Me
t 1
0 m
M
***
***
***
**
***
**
**
**
20
15
10
5
cA
M
P
(pm
ol 
μg
–
1  
pr
ot
ei
n)
0
Met 10 mM – –
+
+
+
+ +
+ ++
++
+
+
+
+
+ +
+
+ +
+
+ +
++
–
–
––
–
– –
–
––
–
– –
–
– –
–
– –
– –
– –
–
–
Fsk 10 μM
6 Hours 12 Hours 24 Hours 48 Hours
αMSH 10 μM
Ctr
Me
t 1
0 m
M
Fs
k 2
0 μ
M
Me
t 1
0 m
M 
+ 
Fs
k 2
0 μ
M
αM
SH
 10
 μM
αM
SH
 10
 μM
 +
 M
et 
10
 m
M Ctr
Me
t 5
 m
M
Fs
k 2
0 μ
M
Me
t 1
0 m
M 
+
Fs
k 2
0 μ
M
Me
t 1
0 m
M
Figure 3. Metformin inhibits protein kinase A (PKA) phosphorylation, cAMP-responsive element–binding protein (CREB) phosphorylation, and cAMP
accumulation. B16-F10 cells (a, c) or normal human melanocytes (b) were incubated with metformin 10 mM (Met), forskolin 20mM (Fsk), alpha-melanocyte
stimulating hormone (a-MSH) 10mM, or a combination of these drugs at the indicated time. Cell lysates were then subjected either to western blotting with the
indicated antibodies (a, b) or to total cAMP dosage according to the manufacturer’s instructions (ArborAssays) (c); data are means±SD of three independent
experiments performed in triplicate (**Pp0.01, ***Pp0.001 versus control, 111Pp0.001, &Pp0.05, &&Pp0.01, &&&Pp0.001). (d) B16-F10 cells were
incubated with metformin 10 mM (Met), dibutyryl cAMP (dbcAMP) 1 mM, or a combination of these compounds, as indicated, for 24 hours. Cell lysates were used
for western blotting with the indicated antibodies. ERK2 was used as a loading control.
A Lehraiki et al.
Metformin Inhibits Melanogenesis
2592 Journal of Investigative Dermatology (2014), Volume 134
photography of the well containing reconstructed human
epidermis after 15 days of stimulation by forskolin and/or
metformin indicated that forskolin increased melanin expres-
sion, whereas metformin inhibited its synthesis. As expected,
western blot analysis (Figure 6b) indicated that forskolin
increased the levels of melanogenesis proteins such as
MITF and tyrosinase. In contrast, metformin abolished
completely the expression of these proteins in basal or
NHM
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Figure 5. Metformin inhibits melanogenesis in vivo. C57BL/6J mice (six mice per group) were topically treated daily on the tail with 10 mM metformin,
20mM forskolin, or a combination prepared in standard dermatologic vehicle consistent of 30% weight:volume solution of 70% ethanol, 30% propylene
glycol during 8 weeks. Solvent control (Ctr) consisted of the same volume of 70% ethanol/30% propylene glycol. Mice tails were photographed using
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control). DCT, dopachrome tautomerase; MITF, microphthalmia-associated transcription factor.
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forskolin-stimulated conditions. To confirm this, another
series of experiments were conducted directly on human
skin biopsies prepared from abdominoplasty. Biopsies were
maintained in culture during 15 days and were stimulated for
2 days each by forskolin and/or metformin. Fontana–Masson
staining was performed on paraffin-frozen skin sections to
detect intracellular melanin (Figure 6c). Forskolin increases
the number of cells that contains melanin, whereas metformin
strongly decreases the number of melanin-positive cells in
control and forskolin-treated conditions. Quantification of
melanin-positive cells (Figure 6d) confirms the Fontana–
masson staining observations.
These data confirmed the results that we obtained in vitro
and demonstrated clearly that metformin has a depigmenting
effect in intact cells, as well as in mice and humans.
DISCUSSION
Melanogenesis, a major function of differentiated melano-
cytes, has an important role in protecting skin from sun-related
injuries and is principally responsible for skin color. Abnormal
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accumulation of melanin pigments is responsible for pigmen-
ted disorders such as melasma and senile lentigo. Current
treatment options are not fully efficient and in several cases
induce side effects. Thus, it is imperative to identify agents
with better efficacy and fewer side effects.
In humans and in mice, it is well established that cAMP
has a critical role in the regulation of melanogenesis through
the activation of the transcription factor CREB (Ao et al., 1998;
Busca and Ballotti, 2000). A recent study reported that
metformin decreases cAMP accumulation in hepatocytes to
antagonize glucagon action (Miller et al., 2013). Then, the
purpose of the present work was to investigate the inhibitory
effects of metformin on melanin formation, which is closely
related to pigmentation of the skin. Our results showed that
metformin decreased melanin production and secretion in a
time- and a dose-dependent manner in B16-F10 melanoma
cells. This effect is due to a sharp decrease in cAMP
accumulation especially in forskolin- or a-MSH-stimulated
conditions, which lead to CREB deactivation and then to a
decrease in master genes of melanogenesis, MITF, Tyrosinase,
DCT, and TRP1. Furthermore, metformin inhibits MITF
promoter activity, suggesting that it regulates MITF at the
transcriptional level. In addition, MITF promoter containing a
mutation in the CREB-binding site is not altered by metformin,
which suggests that the CREB-responsive motifs are essential
for the antimelanogenic effect of metformin.
We already showed that metformin induces cell cycle arrest
of melanoma cells after 24 hours of treatment and apoptosis
after 96 hours of treatment (Tomic et al., 2011). In our study,
metformin reduced MITF and melanogenic gene levels after
12 hours of treatment (Supplementary Figure 3 online). More-
over, metformin did not induce any change in the number of
B16-F10 cells at the short treatment time, which suggests that
the antimelanogenic effect of metformin in melanoma cells is
not related to its effect on cell viability. These observations
suggest that the effect of metformin on pigmentation was
not due to a cytotoxic effect. The antimelanogenic effect of
metformin on NHM cells confirmed this hypothesis. Indeed,
we already showed that metformin had no effect on NHM
viability (Tomic et al., 2011). Here, we showed that
metformin, as in melanoma cells, inhibited melanogenesis
genes in a dose- and a time-dependent manner without
affecting their viability, demonstrating clearly that the effects
of metformin on cell viability and on pigmentation are
independent.
Compelling evidence has been gathered indicating that
metformin action is mainly mediated by AMPK activation
(Zhou et al., 2001; Shaw et al., 2005). As metformin activated
AMPK, we asked whether the kinase was required for the
effects of metformin on melanin production.
In this study, inactivation of AMPK by an AMPK dominant
negative construct or inhibition of AMPK expression by siRNA
did not abrogate the inhibitory effect of metformin on MITF,
indicating that metformin-inhibited melanogenesis seems to
be independent of the AMPK pathway. These results are in
accordance with recently published results demonstrating that
the effects of metformin on glucagon metabolism are inde-
pendent of the AMPK pathway (Miller et al., 2013). However,
expression of Ad-AMPK dominant negative mutant in NHM
cells only partially diminished metformin-dependent activa-
tion of acetyl-CoA carboxylase, one of the major AMPK
substrates. Therefore, we cannot exclude that the residual
AMPK activation by metformin is sufficient to mediate
metformin effect on MITF expression.
In agreement with a recent report (Borgdorff et al., 2014),
we observe that the inhibition of AMPK by either Ad-AMPK
dominant negative mutant (Figure 4a) or Si-AMPK (Figure 4c)
led to significant increases of basal MITF levels in these cells,
suggesting also a role of AMPK in regulating MITF levels.
Taken together, our findings suggest to consider both
AMPK-dependent and AMPK-independent in the control
of MITF in response to metformin. Further, we demonstrate
that metformin suppresses CREB-dependent MITF induction,
which can affect the expression of melanogenic enzymes
by inhibiting cAMP accumulation.
To test whether the effects of metformin on melanogenesis
are representative of its action in vivo, we examined the effect
of metformin on C57BL/6J mouse tail pigmentation. C57BL/6J
mouse tails are highly pigmented, which can explain the lack
of effect of forskolin; moreover, the fact that the concentration
of forskolin that we used might not have been sufficient to
induce a significant increase of melanogenesis in mouse tails
cannot be excluded. We showed that, like in vitro, metformin
is able to inhibit melanogenesis in vivo. Indeed, metformin
induced progressive tail whitening noticeable after 8 weeks
of topical treatment. Further, similar results were obtained
on human reconstituted epidermis and in human skin
biopsies.
These results confirm those obtained in vitro and suggest
that metformin can be used in the treatment of skin hyper-
pigmentation. Our data are in accordance with a beneficial
effect of metformin on the treatment of skin diseases,
especially those associated with hyperinsulinaemia and
hyperandrogenism, such as acne, hidradenitis suppurativa,
acanthosis nigricans, and psoriasis (Ortonne and Passeron,
2005; Cardinali et al., 2012). Interestingly, it is important
to mention that no depigmenting effect has been reported
in diabetic patients treated with metformin. Moreover, we
already showed that systemic treatment of mice with met-
formin induced regression of melanoma tumors. However,
we observed no change of skin pigmentation in metformin-
treated mice compared with untreated mice, suggesting that
the depigmenting effect of metformin is only observed when
used topically.
This study reports the potent inhibitory effect of metformin
on melanogenesis and demonstrates that metformin is a
skin-whitening agent. The inhibitory effects of metformin
were dose- and time-dependent and did not incur significant
cytotoxicity. Considering our results, it is becoming clear
that the antimelanogenic effects of metformin are due to the
inhibition of cAMP/CREB/MITF axis, the most preponderant
pathway involved in melanogenesis.
Taken together, these results prompted us to conclude that
metformin, for which the safety has been validated in a
number of studies, had a therapeutic potential in the treatment
of hyperpigmentation disorders.
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MATERIALS AND METHODS
Cell cultures
NHMs were obtained from the foreskins of Caucasian children, as
described previously (Botton et al., 2009).
B16-F10, Mel501, Skmel28, and G361 melanoma cells were
cultured in DMEM, supplemented with 7% fetal bovine serum
and penicillin/streptomycin (100 IU; 50 g ml 1) and maintained in
5% CO2 at 37 1C.
Reagents and antibodies
Metformin, forskolin, and MCDB153 medium were purchased from
Sigma-Aldrich (Saint Quentin Fallavier, France). Anti-MITF was
obtained from Abcam (Cambridge, MA), and anti-ERK2 (D-2), anti-
DCT, and anti-tyrosinase monoclonal antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). The polyclonal anti-
CREB and anti-phospho-CREB, anti-phospho-PKA, anti-PKA, anti-
phospho-acetyl-CoA carboxylase, and anti-acetyl-CoA carboxylase
were purchased from Cell Signaling Technology (Beverly, MA).
Determination of melanin content
Melanin content was measured as previously described (Bellei
et al., 2010). Briefly, B16 cells (2,5 105 cells per 35-mm well)
were plated for 24 hours and then treated with various concen-
trations of different effectors. Cells were centrifuged and pellets
were photographed and then solubilized in 100ml of 1 M NaOH
in 70 1C for over 2 hours to dissolve melanin, and the absor-
bance was measured spectrophotometrically at 405 nm by using
a plate reader. Melanin production was calculated by norma-
lizing the total melanin values with protein content. The results
are expressed as fold of stimulation compared with control
conditions.
Western blot assays
Cells were grown in six-well dishes with or without different
effectors at the time indicated in the corresponding figure. Cells were
then lysed and western blot analysis was performed as described
(Tomic et al., 2011).
The western blot assays were representative of at least three
independent experiments.
cAMP immunoassay
The cAMP concentration was measured using a cAMP immuno-
assay kit (ArborAssays, Ann Arbor, MI). Briefly, B16 cells were lysed
in 0.1 M HCl to inhibit the phosphodiesterase activity. The super-
natants were collected, neutralized, and diluted, and then a fixed
amount of cAMP conjugate was added to compete with the
cAMP. Next, a substrate solution was added to the wells to
determine the bound enzyme activity. The color development
was stopped, and the absorbance at 420 nm was then read.
The level of cAMP in the sample was determined based on a standard
curve.
Transient transfection of siRNA
Briefly, a single pulse of 50 nmol l 1 of siRNA was administrated to
the cells at 50% confluency by transfection with 5ml of Lipofectamine
RNAiMAX in Opti-MEM medium (Invitrogen, Washington, DC) for
the time indicated in the figure legends. Control scrambled and
AMPK-specific SiRNA were purchased from Invitrogen.
Luciferase reporter assays
B16-F10 cells were seeded in 24-well dishes, and transient transfec-
tions were performed the following day, as described previously
(Bertolotto et al., 1996). Briefly, cells were transiently transfected with
0.5 mg of MITF promoter (p-MITF) and 0.05mg of pCMVbGal to
control the variability in transfection efficiency. The transfection
medium was changed 6 hours later with DMEM supplemented with
7% fetal bovine serum and cells were exposed to drugs. At 48 hours
after transfection, soluble extracts were harvested in lysis buffer and
assayed for luciferase and b-galactosidase activities. All transfections
were repeated at least five times.
Infection of dominant-negative AMPK
Adenovirus encoding a dominant negative form of AMPK was a
generous gift from Dr Foufelle (INSERM, UMR-S /872, Paris, France).
An adenovirus whose expression cassette contains the major late
promoter with no exogenous gene was used as the control (AdCon-
trol). NHM or Mel501 cells were seeded on 6-well plates to reach
90% confluence and then transfected either with a dominant negative
form of AMPK or AdControl. After 24 hours of transfection, the
medium was changed to DMEM with 7% fetal bovine serum, and
cells were exposed to different drugs for another 24 hours.
In vivo experiments
Animal experiments were carried out in accordance with the
Declaration of Helsinki Principles and were approved by a local
ethics committee.
Drugs were prepared as a 30% weight:volume solution in a
standard dermatologic vehicle of 70% ethanol and 30% propylene
glycol (Sigma-Aldrich, St Louis, MO).
C57BL/6J mice of 8 weeks of age were used for this experiment.
Preparations of agents were applied to the tail with a micropipette
and then smoothened out over the tail with the side of a pipette tip so
that a similar amount of solution would be applied to the entire tail.
Animals were treated daily with 400ml of different agents for 8 weeks.
Animals were killed by CO2 narcosis before tail skin sampling to
evaluate melanin content and the melanogenic gene transcription.
Reconstructed human epidermis model
SkinEthic Reconstructed Human Epidermis (SkinEthic RHE) (Ski-
nEthic, Lyon, France) consists of fully differentiated three-dimensional
epidermal tissue grown from normal human keratinocytes for 17 days
in a chemically defined medium at the air–liquid interface. The three-
dimensional reconstructed epidermis was received on day 18, and
preincubated for 24 hours in a growth culture medium (SkinEthic) at
37 1C, 5% CO2, according to SkinEthics procedures. SkinEthic RHE
were treated with different drugs as indicated, and the medium was
changed every 2 days. After 2 weeks of treatment, the RHE was
separated from the polycarbonate support and stored at  80 1C
before analysis.
Human skin punch biopsy
Normal human samples were obtained from an abdominoplasty
surgery patient. The skin punch biopsy was obtained according to
the standard procedure by using a 4-mm-round Visipunch instrument
(Kai Medical, Tokyo, Japan) and then kept in complete DMEM 10%
fetal bovine serum medium. Skin punches are typically between 2
and 5 mm in diameter and extend to a depth ofB4 mm. The skin cell
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constructs were cultured for 15 days and the medium was changed
every 2 days with the corresponding drugs. All human skin samples
were donated with informed consent and with the approval of the
CHU de Nice ethics committee following the Declaration of Helsinki
protocols.
Fontana–Masson staining
A silver stain kit to stain human skin melanin was used according to
the manufacturer’s instructions (Interchim, Montluc¸on, France).
Statistical analysis
Data presented are mean±SD of three independent experiments
performed in triplicate. Statistical significance was assessed using
the Student’s t-test except for in vivo experiments, in which
statistical significance was assessed using a two-tailed Wilcoxon
rank sum test. A value of Pp0.05 was accepted as statistically
significant when comparing experimental and control groups.
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